Literature DB >> 27862602

Active surveillance for favorable-risk prostate cancer: Is there a greater psychological impact than previously thought? A systematic, mixed studies literature review.

Eimear Ruane-McAteer1, Sam Porter2, Joe M O'Sullivan3,4, Olinda Santin1, Gillian Prue1.   

Abstract

OBJECTIVE: Active surveillance (AS) allows men with favorable-risk prostate cancer to avoid or postpone active treatment and hence spares potential adverse effects for a significant proportion of these patients. Active surveillance may create an additional emotional burden for these patients. The aim of the review was to determine the psychological impact of AS to inform future study in this area and to provide recommendations for clinical practice.
METHODS: Studies were identified through database searching from inception to September 2015. Quantitative or qualitative noninterventional studies published in English that assessed the psychological impact of AS were included. The Mixed Methods Appraisal Tool was used to assess methodological quality.
RESULTS: Twenty-three papers were included (20 quantitative and 3 qualitative). Quantitatively, the majority of patients do not report psychological difficulties; however, when appropriateness of study design is considered, the conclusion that AS has minimal impact on well-being may not be accurate. This is due to small sample sizes, inappropriately timed baseline, and inappropriate/lack of comparison groups. In addition, a mismatch in outcome was noted between the outcome of quantitative and qualitative studies in uncertainty, with qualitative studies indicating a greater psychological impact.
CONCLUSIONS: Because of methodological concerns, many quantitative studies may not provide a true account of the burden of AS. Further mixed-methods studies are necessary to address the limitations highlighted and to provide clarity on the impact of AS. Practitioners should be aware that despite findings of previous reviews, patients may require additional emotional support.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  active surveillance; anxiety; cancer; depression; oncology; prostatic neoplasms; uncertainty

Mesh:

Year:  2016        PMID: 27862602     DOI: 10.1002/pon.4311

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  13 in total

1.  A feasibility study of a psycho-educational support intervention for men with prostate cancer on active surveillance.

Authors:  John G Hughes; Geraldine M Leydon; Sam Watts; Stephanie Hughes; Lucy A Brindle; Emily Arden-Close; Roger Bacon; Brian Birch; Lallita Carballo; Hilary Plant; Caroline M Moore; Beth Stuart; Guiqing Yao; George Lewith; Alison Richardson
Journal:  Cancer Rep (Hoboken)       Date:  2019-12-09

2.  Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Julia Wade; Sian Noble; Kirsty Garfield; Grace Young; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Jane Blazeby; Richard Bryant; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Vincent Gnanapragasam; Owen Hughes; Roger Kockelbergh; Howard Kynaston; Alan Paul; Edgar Paez; Philip Powell; Stephen Prescott; Derek Rosario; Edward Rowe; David Neal
Journal:  Health Technol Assess       Date:  2020-08       Impact factor: 4.014

Review 3.  Cognitive and Psychological Impacts of Different Treatment Options for Prostate Cancer: A Critical Analysis.

Authors:  Konstantina G Yiannopoulou; Aikaterini I Anastasiou; Konstantinos Kontoangelos; Charalambos Papageorgiou; Ioannis P Anastasiou
Journal:  Curr Urol       Date:  2020-12-18

Review 4.  Patient and provider experiences with active surveillance: A scoping review.

Authors:  Claire Kim; Frances C Wright; Nicole J Look Hong; Gary Groot; Lucy Helyer; Pamela Meiers; May Lynn Quan; Robin Urquhart; Rebecca Warburton; Anna R Gagliardi
Journal:  PLoS One       Date:  2018-02-05       Impact factor: 3.240

5.  "Still a Cancer Patient"-Associations of Cancer Identity With Patient-Reported Outcomes and Health Care Use Among Cancer Survivors.

Authors:  Melissa S Y Thong; Eva-Maria Wolschon; Lena Koch-Gallenkamp; Annika Waldmann; Mechthild Waldeyer-Sauerland; Ron Pritzkuleit; Heike Bertram; Hiltraud Kajüter; Andrea Eberle; Bernd Holleczek; Sylke R Zeissig; Hermann Brenner; Volker Arndt
Journal:  JNCI Cancer Spectr       Date:  2018-07-05

6.  Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial.

Authors:  Julia Wade; Jenny Donovan; Athene Lane; Michael Davis; Eleanor Walsh; David Neal; Emma Turner; Richard Martin; Chris Metcalfe; Tim Peters; Freddie Hamdy; Roger Kockelbergh; James Catto; Alan Paul; Peter Holding; Derek Rosario; Howard Kynaston; Edward Rowe; Owen Hughes; Prasad Bollina; David Gillatt; Alan Doherty; Vincent J Gnanapragasam; Edgar Paez
Journal:  BMJ Open       Date:  2020-09-09       Impact factor: 2.692

7.  Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners.

Authors:  Tim J Hartung; Ida Rask Moustsen; Signe Benzon Larsen; Elisabeth A Wreford Andersen; Nis P Suppli; Christoffer Johansen; Anne Tjønneland; Anne S Friberg; Susanne K Kjær; Klaus Brasso; Lars V Kessing; Anja Mehnert; Susanne Oksbjerg Dalton
Journal:  J Cancer Surviv       Date:  2020-10-13       Impact factor: 4.442

8.  Potential Epigenetic Biomarkers for Prostate Cancer Screening.

Authors:  Jong-Myon Bae
Journal:  Int Neurourol J       Date:  2018-06-30       Impact factor: 2.835

9.  Duration of sick leave after active surveillance, surgery or radiotherapy for localised prostate cancer: a nationwide cohort study.

Authors:  Anna Plym; Mark Clements; Margaretha Voss; Lars Holmberg; Pär Stattin; Mats Lambe
Journal:  BMJ Open       Date:  2020-03-09       Impact factor: 2.692

Review 10.  Depression and prostate cancer: implications for urologists and oncologists.

Authors:  Christopher F Sharpley; David R H Christie; Vicki Bitsika
Journal:  Nat Rev Urol       Date:  2020-07-30       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.